Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis

References

• Cesarman E, Chang Y, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–1191.
   PubMed Web of Science ®Google Scholar
• Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28:1401–1416.
   PubMed Web of Science ®Google Scholar
• Carbone A, Volpi CC, Caccia D, et al. Extracavitary KSHV-positive solid lymphoma: a large B-cell lymphoma within the spectrum of primary effusion lymphoma. Am J Surg Pathol. 2013;37:1460–1461.
   PubMed Web of Science ®Google Scholar
• Gloghini A, Volpi CC, Caccia D, et al. Primary effusion lymphoma: secretome analysis reveals novel candidate biomarkers with potential pathogenetic significance. Am J Pathol. 2014;184:618–630.
   PubMed Web of Science ®Google Scholar
• Fend F, Cabecadas J, Gaulard P, et al. Early lesion in lymphoid neoplasia. J Hematopathol. 2012;5:169–199.
   Google Scholar
• Carbone A, De Paoli P, Gloghini A, et al. KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies. Int J Cancer. 2015;137:251–261.
   PubMed Web of Science ®Google Scholar
• Carbone A, Vaccher E, Gloghini A, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol. 2014;11:223–238.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Clauvel JP, Jouveshomme S, et al. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol. 1998;57:266.
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Agbalika F, Oksenhendler E, et al. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS. 2001;15:280–282.
   PubMed Web of Science ®Google Scholar
• Ripamonti D, Marini B, Rambaldi A, et al. Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection. AIDS. 2008;22:1236–1237.
   PubMed Web of Science ®Google Scholar
• Gloghini A, Dolcetti R, Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol. 2013;23:457–467.
   PubMed Web of Science ®Google Scholar
• Capello D, Gaidano G, Gallicchio M, et al. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia. 2000;14:285–291.
   PubMed Web of Science ®Google Scholar
• Dai L, Trillo-Tinoco J, Cao Y, et al. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood. 2015;126:2821–2831.
   PubMed Web of Science ®Google Scholar
• Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005;33(Web Server issue):W741–8.
   PubMed Web of Science ®Google Scholar
• Wang J, Duncan D, Shi Z, et al. WEB-based GEne SeT analysis toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41(Web Server issue):W77–83.
   PubMed Web of Science ®Google Scholar
• Moroianu J, Blobel G, Radu A. Nuclear protein import: ran-GTP dissociates the karyopherin alphabeta heterodimer by displacing alpha from an overlapping binding site on beta. Proc Natl Acad Sci USA. 1996;93:7059–7062.
   PubMed Web of Science ®Google Scholar
• Ribbeck K, Lipowsky G, Kent HM, et al. NTF2 mediates nuclear import of Ran. EMBO J. 1998;17:6587–6598.
   PubMed Web of Science ®Google Scholar
• Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155–165.
   PubMed Web of Science ®Google Scholar
• Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood. 2013;122:3034–3044.
   PubMed Web of Science ®Google Scholar
• Kojima K, Kornblau SM, Ruvolo V. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121:4166–4174.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120:1765–1773.
   PubMed Web of Science ®Google Scholar
• Chang KC, Chang WC, Chang Y, et al. Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PLoS One. 2013;8:e79863.
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373–383.
   PubMed Web of Science ®Google Scholar
• van Niel G, Porto-Carreiro I, Simoes S, et al. Exosomes: a common pathway for a specialized function. J Biochem. 2006;140:13–21.
   PubMed Web of Science ®Google Scholar
• Gutzeit C, Nagy N, Gentile M, et al. Exosomes derived from Burkitt’s lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells. J Immunol. 2014;192:5852–5862.
   PubMed Web of Science ®Google Scholar
• Meckes DG Jr, Gunawardena HP, Dekroon RM, et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci USA. 2013;110:E2925–33.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents. IARC working group on the evaluation of carcinogenic risks to humans. Vol. 100. Lyon: IARC; 2012.
   Google Scholar
• Arvey A, Ojesina AI, Pedamallu CS, et al. The tumor virus landscape of AIDS-related lymphomas. Blood. 2015;125:e14–e22.
   PubMed Web of Science ®Google Scholar
• Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113:1213–1224.
   PubMed Web of Science ®Google Scholar
• Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4:22–29.
   PubMed Web of Science ®Google Scholar
• Chadburn A, Abdul-Nabi AM, Teruya BS, et al. Lymphoid proliferations associated with human immunodeficiency virus infection. Arch Pathol Lab Med. 2013;137:360–370.
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Dal Col J, Martorelli D, et al. Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. Semin Cancer Biol. 2013;23:441–456.
   PubMed Web of Science ®Google Scholar
• Jha HC, Banerjee S, Robertson ES. The role of gammaherpesviruses in cancer pathogenesis. Pathogens. 2016;5:18. .
   Web of Science ®Google Scholar
• Kelesidis T, Tran TT, Stein JH, et al. Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis. 2015;61:651–660.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788–1795.
   PubMed Web of Science ®Google Scholar
• Regidor DL, Detels R, Breen EC, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS. 2011;25:303–314.
   PubMed Web of Science ®Google Scholar
• Popovic M, Tenner-Racz K, Pelser C, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2005;102:14807–14812.
   PubMed Web of Science ®Google Scholar
• Banga R, Procopio FA, Noto A, et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med. 2016;22:754–761.
   PubMed Web of Science ®Google Scholar
• Kundu RK, Sangiorgi F, Wu LY, et al. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood. 1999;94:275–282.
   PubMed Web of Science ®Google Scholar
• Curreli S, Krishnan S, Reitz M, et al. B cell lymphoma in HIV transgenic mice. Retrovirology. 2013;10:92.
   PubMed Web of Science ®Google Scholar
• Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis. 2009;200:79–87.
   PubMed Web of Science ®Google Scholar
• Achenbach CJ, Buchanan AL, Cole SR, et al. HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014;58:1599–1606.
   PubMed Web of Science ®Google Scholar
• INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Giagulli C, He W, et al. Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proc Natl Acad Sci USA. 2015;112:14331–14336.
   PubMed Web of Science ®Google Scholar
• Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000;156:743–749.
   PubMed Web of Science ®Google Scholar
• Schulz TF, Cesarman E. Kaposi sarcoma-associated herpesvirus: mechanisms of oncogenesis. Curr Opin Virol. 2015;14:116–128.
   PubMed Web of Science ®Google Scholar
• Pantanowitz L, Carbone A, Dolcetti R. Microenvironment and HIV-related lymphomagenesis. Semin Cancer Biol. 2015;34:52–57.
   PubMed Web of Science ®Google Scholar
• Greene W, Kuhne K, Ye F, et al. Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res. 2007;133:69–127.
   PubMedGoogle Scholar
• Zeng Y, Zhang X, Huang Z, et al. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi’s sarcoma-associated herpesvirus: role of JAK/STAT signaling. J Virol. 2007;81:2401–2417.
   PubMed Web of Science ®Google Scholar
• Yan Q, Shen C, Qin J, et al. HIV-1 Vpr inhibits Kaposi’s sarcoma-associated herpesvirus lytic replication by inducing microRNA miR-942-5p and activating NF-κB signaling. J Virol. 2016;90:8739–8753.
   PubMed Web of Science ®Google Scholar
• Yan Q, Ma X, Shen C, et al. Inhibition of Kaposi’s sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258. J Virol. 2014;88:4987–5000.
   PubMed Web of Science ®Google Scholar
• Van Baarle D, Wolthers KC, Hovenkamp E, et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis. 2002;186:405–409.
   PubMed Web of Science ®Google Scholar
• Piriou ER, van Dort K, Nanlohy NM, et al. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol. 2004;172:6931–6937.
   PubMed Web of Science ®Google Scholar
• Leruez-Ville M, Seng R, Morand P, et al. Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma. HIV Med. 2012;13:479–487.
   PubMed Web of Science ®Google Scholar
• Hamoudi R, Diss TC, Oksenhendler E, et al. Distinct cellular origins of primary effusion lymphoma with and without EBV infection. Leuk Res. 2004;28:333–338.
   PubMed Web of Science ®Google Scholar
• Mack AA, Sugden B. EBV is necessary for proliferation of dually infected primary effusion lymphoma cells. Cancer Res. 2008;68:6963–6968.
   PubMed Web of Science ®Google Scholar
• Simonelli C, Tedeschi R, Gloghini A, et al. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis. 2005;40:1022–1027.
   PubMed Web of Science ®Google Scholar
• Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s sarcoma-associated herpesvirus/human herpesvirus-8. Blood. 1997;90:1186–1191.
   PubMed Web of Science ®Google Scholar
• Dittmer DP, Damania B. Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. J Clin Invest. 2016;126:3165–3175.
   PubMed Web of Science ®Google Scholar
• Shin YC, Nakamura H, Liang X, et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi’s sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol. 2006;80:2257–2266.
   PubMed Web of Science ®Google Scholar
• Seo T, Park J, Choe J. Kaposi’s sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling. Cancer Res. 2005;65:1738–1747.
   PubMed Web of Science ®Google Scholar
• De Paoli P, Carbone A. Microenvironmental abnormalities induced by viral cooperation: impact on lymphomagenesis. Semin Cancer Biol. 2015;34:70–80.
   PubMed Web of Science ®Google Scholar
• Carbone A, Cilia AM, Gloghini A, et al. Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma. Leukemia. 2000;14:1301–1309.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu D, Zhao Y, et al. Mutual inhibition between Kaposi’s sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators individually-infected primary effusion lymphoma. PLoS One. 2008;3:e1569.
   PubMed Web of Science ®Google Scholar
• Spadavecchia S, Gonzalez-Lopez O, Carroll KD, et al. Convergence of Kaposi’s sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol. 2010;84:10488–10500.
   PubMed Web of Science ®Google Scholar
• Piedade D, Azevedo-Pereira JM. The role of microRNAs in the pathogenesis of herpesvirus infection. Viruses. 2016;8:156.
   PubMed Web of Science ®Google Scholar
• Minarovits J, Demcsák A, Banati F, et al. Epigenetic dysregulation in virus-associated neoplasms. Adv Exp Med Biol. 2016;879:71–90.
   PubMed Web of Science ®Google Scholar
• Jha HC, Yang K, El-Naccache DW, et al. EBNA3C regulates p53 through induction of aurora kinase B. Oncotarget. 2015;6:5788–5803.
   PubMed Web of Science ®Google Scholar
• Cavignac Y, Esclatine A. Herpesviruses and autophagy: catch me if you can! Viruses. 2010;2:314–333.
   PubMed Web of Science ®Google Scholar
• Castanier C, Arnoult D. Mitochondrial localization of viral proteins as a means to subvert host defense. Biochim Biophys Acta. 2011;1813:575–583.
   PubMed Web of Science ®Google Scholar
• Carbone A, Cesarman E, Gloghini A, et al. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS. 2010;24:479–490.
   PubMed Web of Science ®Google Scholar